Switzerland
· Delayed Price · Currency is CHF Newron Pharmaceuticals Statistics
Total Valuation
Newron Pharmaceuticals has a market cap or net worth of CHF 161.81 million. The enterprise value is 195.15 million.
| Market Cap | 161.81M |
| Enterprise Value | 195.15M |
Important Dates
The next estimated earnings date is Monday, September 30, 2024.
| Earnings Date | Sep 30, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Newron Pharmaceuticals has 19.06 million shares outstanding. The number of shares has increased by 48.58% in one year.
| Shares Outstanding | 19.06M |
| Shares Change (YoY) | +48.58% |
| Shares Change (QoQ) | +33.52% |
| Owned by Insiders (%) | 5.10% |
| Owned by Institutions (%) | 4.81% |
| Float | 18.09M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 12.86 |
| PS Ratio | 17.97 |
| PB Ratio | n/a |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -12.92 |
| EV / Sales | 23.15 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -20.65 |
Financial Position
The company has a current ratio of 0.68
| Current Ratio | 0.68 |
| Quick Ratio | 0.61 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | -4.77 |
| Interest Coverage | -2.79 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -23.05% |
| Return on Capital (ROIC) | -28.99% |
| Revenue Per Employee | 383,178 |
| Profits Per Employee | -686,394 |
| Employee Count | 22 |
| Asset Turnover | 0.29 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +43.31% in the last 52 weeks. The beta is 0.70, so Newron Pharmaceuticals's price volatility has been lower than the market average.
| Beta (5Y) | 0.70 |
| 52-Week Price Change | +43.31% |
| 50-Day Moving Average | 7.99 |
| 200-Day Moving Average | 7.83 |
| Relative Strength Index (RSI) | 61.02 |
| Average Volume (20 Days) | 39,490 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Newron Pharmaceuticals had revenue of CHF 8.43 million and -15.10 million in losses. Loss per share was -0.85.
| Revenue | 8.43M |
| Gross Profit | 8.43M |
| Operating Income | -10.82M |
| Pretax Income | -15.08M |
| Net Income | -15.10M |
| EBITDA | -10.70M |
| EBIT | -10.82M |
| Loss Per Share | -0.85 |
Balance Sheet
The company has 11.73 million in cash and 45.06 million in debt, giving a net cash position of -33.34 million or -1.75 per share.
| Cash & Cash Equivalents | 11.73M |
| Total Debt | 45.06M |
| Net Cash | -33.34M |
| Net Cash Per Share | -1.75 |
| Equity (Book Value) | -27.84M |
| Book Value Per Share | -1.56 |
| Working Capital | -8.63M |
Cash Flow
In the last 12 months, operating cash flow was -9.44 million and capital expenditures -10,238, giving a free cash flow of -9.45 million.
| Operating Cash Flow | -9.44M |
| Capital Expenditures | -10,238 |
| Free Cash Flow | -9.45M |
| FCF Per Share | -0.50 |
Margins
Gross margin is 100.00%, with operating and profit margins of -128.40% and -179.13%.
| Gross Margin | 100.00% |
| Operating Margin | -128.40% |
| Pretax Margin | -178.87% |
| Profit Margin | -179.13% |
| EBITDA Margin | -126.89% |
| EBIT Margin | -128.40% |
| FCF Margin | -112.08% |
Dividends & Yields
Newron Pharmaceuticals does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -48.58% |
| Shareholder Yield | -48.58% |
| Earnings Yield | -9.97% |
| FCF Yield | -5.84% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |